Veracyte Completes $28 Million Series B Round – One Step Closer to Commercializing First Molecular Diagnostic Product SOUTH SAN FRANCISCO, Calif.--- BUSINESS WIRE ---Veracyte, Inc. announced today the successful completion of its Series B round, a key milestone toward the company’s first product
New Data Suggest Veracyte's Molecular Test Improves Accuracy of Thyroid Nodule Diagnosis Using Fine Needle Aspirate (FNA) Samples South San Francisco, Calif.--- PRNewswire ---Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, announced that initial
New Data Suggest Veracyte’s Afirma® Gene Expression Classifier Cost-Effectively Resolves Inconclusive Thyroid Nodule FNA Biopsy Results South San Francisco, Calif. --- September 1, 2011 --- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today
Veracyte Announces Medicare Coverage for Its Afirma® Gene Expression Classifier for Improved Thyroid Nodule Diagnosis South San Francisco, Calif. --- January 9, 2012 --- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced that
Genzyme and Veracyte Announce Global Co-Promotion Agreement to Deliver Personalized Solution for Thyroid Patients Cambridge, Mass. and South San Francisco, Calif. --- January 20, 2012 --- Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY) and one of the world’s leading biotechnology companies,
Richard T. Kloos, MD, Joins Veracyte as Senior Medical Director South San Francisco, Calif. --- April 5, 2012 --- Veracyte, Inc. , a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced the appointment of Richard T.
Genzyme and Veracyte Announce Expanded U.S. Availability of the Afirma® Thyroid FNA Analysis for Improved Thyroid Nodule Diagnosis Cambridge, Mass. and South San Francisco, Calif. --- Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY ), and Veracyte, Inc., a molecular diagnostics company
New Study Suggests That Use of Veracyte’s Afirma® Gene Expression Classifier Helps to Significantly Reduce Surgeries in Patients with Ambiguous Thyroid Nodule Cytology Results South San Francisco, Calif. and Cambridge, Mass. — July 17, 2012 — Veracyte, Inc.
Veracyte and Genzyme Also Announce that Memorial Sloan-Kettering Cancer Center is Among the State’s First Institutions to Offer Genomic Test to Patients with Inconclusive Thyroid Nodule Results
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.
